Meeting
2020 ASCO Quality Care Symposium
Evaluating compliance of NCCN cancer and chemotherapy-induced anemia guidelines in a community healthcare setting.
Authors
Jamie Haber
University of Connecticut Department of Medicine, Farmington, CT
Jamie Haber, Brian J. Byrne
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
On-Demand Poster Session: Cost, Value, and Policy
Track
Cost, Value, and Policy
Sub Track
Guideline-Concordant Care Initiatives
Citation
J Clin Oncol 38, 2020 (suppl 29; abstr 16)
DOI
10.1200/JCO.2020.38.29_suppl.16
Abstract #
16
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Quality Care Symposium
Clinical and economic effects of technology updates to the electronic health record for the management of erythopoetic stimulating agents and MDS-associated anemia.
First Author: Steven Gilmore
Poster
2024 ASCO Annual Meeting
Clinical benefit of luspatercept treatment (tx) in transfusion-dependent (TD), erythropoiesis-stimulating agent (ESA)–naive patients (pts) with very low-, low- or intermediate-risk myelodysplastic syndromes (MDS) in the COMMANDS trial.
First Author: Amer Methqal Zeidan
Poster
2022 ASCO Annual Meeting
Increasing the use of olanzapine in patients receiving chemotherapy in a community oncology practice.
First Author: Bindu Rani Potugari
Poster
2020 ASCO Virtual Scientific Program
Clinical benefit of luspatercept in patients (pts) with lower-risk MDS (LR-MDS) and high transfusion burden in the phase III MEDALIST study.
First Author: Amer Methqal Zeidan